Livdelzi (seladelpar): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Livdelzi (seladelpar) is one of those medicines that sounds like a sci-fi planet but is actually a real prescription drug for a real,
very unglamorous liver condition: primary biliary cholangitis (PBC).
If you’ve ever tried explaining PBC at a family dinner (“No, it’s not about gallstones… yes, it’s autoimmune… no, I can’t just ‘detox’ it…”),
you already deserve dessert.

This guide walks through what Livdelzi is used for, how it works, what side effects to watch, the most important drug interactions,
how to identify the capsule, and what “accelerated approval” actually means (spoiler: it’s not a fast lane at the pharmacy).

What Is Livdelzi (seladelpar)?

Livdelzi is a prescription medication that contains seladelpar (commonly provided as seladelpar lysine in product labeling).
It’s classified as a PPAR-delta (PPARδ) agonist. Translation: it activates a receptor involved in metabolic and inflammatory pathways,
including pathways that influence bile acid production.

Livdelzi is approved in the U.S. for adults with primary biliary cholangitis (PBC):

• In combination with ursodeoxycholic acid (UDCA/ursodiol) if UDCA alone didn’t work well enough, or
• As monotherapy if someone can’t tolerate UDCA.

The FDA approval is under accelerated approval, meaning the medication was approved based on improvement in a surrogate marker
(like liver lab improvements) while confirmatory studies continue. In plain terms:
it’s shown it can improve important lab numbers, but it’s not yet proven to improve survival or prevent liver decompensation events.

How Livdelzi Works (and Why PBC Lab Numbers Matter)

PBC is an autoimmune disease where small bile ducts in the liver are gradually damaged.
When bile can’t flow normally, bile acids and other compounds build up, contributing to liver inflammation and, over time, scarring.

Seladelpar activates PPARδ, and published research described in prescribing information indicates PPARδ activation by seladelpar
can reduce bile acid synthesis through a pathway involving FGF21 and downregulation of CYP7A1
(a key enzyme in bile acid production).
Fewer bile acids being produced can mean less cholestatic stress on the liver.

In clinical studies, Livdelzi improved common PBC biomarkers such as alkaline phosphatase (ALP).
ALP is a cholestasis marker; persistently elevated ALP is associated with worse outcomes in PBC, which is why clinicians care so much about it.
(Yes, even if ALP sounds like a 90s boy band.)

Uses: When Livdelzi Is Prescribed

1) Add-on therapy when UDCA isn’t enough

UDCA (ursodiol) is the usual first-line treatment for PBC because it can improve liver tests and slow progression in many people.
But not everyone gets an adequate response. If labs remain above targetespecially ALPyour clinician may consider adding another medication.
Livdelzi is one option for that “UDCA wasn’t quite the full solution” scenario.

2) Monotherapy if UDCA can’t be tolerated

Some people can’t take UDCA due to side effects or intolerance. In that case, Livdelzi may be used on its own.
In trials supporting approval, most participants used it with UDCA, and a smaller portion used it as monotherapy.

What improvement can look like (a real example from clinical trials)

In a pivotal PBC trial, “biochemical response” was defined using a combination of lab thresholds:
ALP under a certain level, a meaningful ALP reduction, and bilirubin within normal limits.
At 12 months, the Livdelzi group showed a higher biochemical response rate compared with placebo.
There was also a meaningful reduction in ALP as early as one month that tended to persist through 12 months.

Itching (pruritus): a symptom people actually feel

PBC itching can be brutal“mosquito bite season, but inside your skin” brutal.
In the pivotal trial, patients with more significant baseline itching (pruritus score ≥4 on a 0–10 scale) had greater improvement with Livdelzi than placebo at 6 months.
That doesn’t mean everyone will have itch relief, but it’s a meaningful finding because it targets quality of life, not just lab spreadsheets.

Dosing & Administration

Standard dosing

The recommended dose for adults is 10 mg by mouth once daily.
You can take it with or without food.

Timing with bile acid sequestrants (very important)

If you take a bile acid sequestrant (also called bile acid binding resin) such as
cholestyramine, colestipol, or colesevelamoften used for itching or cholesterol
it can reduce Livdelzi absorption.
The usual instruction is to take Livdelzi at least 4 hours before or 4 hours after the sequestrant, or as far apart as possible.

If you miss a dose

General practice (and what many clinicians recommend for once-daily meds): take it when you remember unless it’s close to your next dose.
If it’s close, skip the missed dosedon’t double up.
When in doubt, follow your prescriber’s instructions because your situation (and other meds) matter.

Storage

Store at controlled room temperature, away from excessive heat and moisture, and keep out of reach of kids and pets
(who, unlike adults, do not read the warning label and have no respect for “child-resistant” anything).

Side Effects

Every medication has side effects. The goal is not “zero side effects forever,” but “benefits outweigh risks, and we monitor the stuff that matters.”
Here’s what’s been reported.

Most common side effects (seen more often than placebo)

• Headache
• Abdominal pain
• Nausea
• Abdominal distension (bloating)
• Dizziness

Less common side effects reported

In clinical data, additional reactions occurred more often than placebo but in fewer than 5% of people, including:
dyspepsia (indigestion), rash, alopecia (hair thinning/loss),
anemia, and cough.

Lab-related changes you might see

In a major trial, some patients had decreases in estimated glomerular filtration rate (eGFR), a measure related to kidney function,
more frequently than placebo. In that trial, these changes generally stabilized or moved back toward baseline without requiring discontinuation.
Your clinician may monitor kidney-related labs along with liver labs as part of routine care.

When side effects deserve a faster phone call

Contact your healthcare team promptly if you notice symptoms that could suggest worsening liver problems or biliary obstruction, including:
yellowing of the skin/eyes, dark urine, severe right upper abdominal pain, swelling in the belly, vomiting blood, black/tarry stools,
or sudden confusion/sleepiness. Those are “don’t wait for next week’s appointment” symptoms.

Warnings & Precautions

1) Fractures (bone health matters)

Livdelzi treatment has been associated with an increased risk of bone fractures in clinical data.
PBC itself can be associated with bone health issues in some patients, so this is not a “random left-field warning.”
Clinicians may monitor bone health according to standard practice (for example, considering bone density testing when appropriate).

2) Liver test abnormalities (especially at high doses)

Seladelpar has been associated with dose-related increases in AST/ALT (liver enzymes) at doses well above the recommended 10 mg daily dose.
The recommended dose did not show the same pattern, but liver lab monitoring is still part of safe use.
Baseline labs are obtained, and periodic monitoring continues during treatment.
If liver tests worsen or symptoms suggest clinical hepatitis, clinicians may interrupt the medication and evaluate.

3) Biliary obstruction

Livdelzi should be avoided in complete biliary obstruction.
If biliary obstruction is suspected (for example, new jaundice with right upper abdominal pain), treatment is typically interrupted while evaluation happens.

4) Advanced liver disease (decompensated cirrhosis)

Use is not recommended in people who have or develop decompensated cirrhosismeaning cirrhosis with complications
such as ascites (fluid in the abdomen), variceal bleeding, or hepatic encephalopathy.
Patients with cirrhosis may be monitored for signs of decompensation, and therapy may be reconsidered if liver function worsens.

5) Pregnancy and breastfeeding

There is limited human pregnancy data, so clinicians weigh risks and benefits carefully.
If pregnancy occurs, patients are generally advised to notify their provider promptly.
It’s also not known if seladelpar passes into breast milk; decisions about breastfeeding should be individualized with a clinician.

6) Overdose considerations

At doses many times higher than recommended, reports include increased liver enzymes and muscle-related symptoms with elevated creatine phosphokinase (CPK),
resolving after stopping the medication. If overdose is suspected, urgent medical evaluation is appropriate.

Drug Interactions

Interactions are where many “good meds” become “complicated meds.”
Here are the interactions most often emphasized in professional prescribing information, translated into everyday language.

Bile acid sequestrants (binding resins)

These can reduce Livdelzi absorption.
Separate doses by 4 hours before or 4 hours after (or as far apart as possible).
Common examples include cholestyramine, colestipol, and colesevelam.

OAT3 inhibitors (avoid)

OAT3 inhibitors can raise seladelpar exposure. A commonly cited example is probenecid.
The typical recommendation is to avoid concomitant use.

Strong CYP2C9 inhibitors (avoid)

Seladelpar is primarily metabolized by CYP2C9, so strong CYP2C9 inhibitors can increase exposure.
The labeling generally advises avoiding strong inhibitors in this class. (Your clinician/pharmacist will know which ones qualify as “strong.”)

Rifampin (monitor response)

Rifampin can lower seladelpar exposure and may reduce biochemical response.
This one matters in the real world because rifampin is sometimes used to help PBC itching.
If rifampin is started, clinicians may monitor ALP and bilirubin and adjust the overall plan if response changes.

Dual CYP inhibitors and special metabolism scenarios

Some medications inhibit both CYP2C9 and CYP3A4 to varying degrees (for example, certain antifungals).
When seladelpar exposure increases, clinicians may monitor more closely for side effects.
Additionally, people with CYP2C9 poor metabolizer genetics who also take moderate-to-strong CYP3A4 inhibitors may have higher exposure,
so monitoring can be more frequent in that scenario.

BCRP inhibitors (monitor closely)

Drugs that inhibit BCRP (a transporter involved in drug movement) may increase seladelpar exposure.
A commonly cited example is cyclosporine. The typical advice is closer monitoring for adverse effects.

Bottom line: bring a complete medication list to appointments, including over-the-counter meds, vitamins, and herbal supplements.
Your pharmacist is not being nosythey’re trying to keep your liver from starring in a horror movie.

Pictures: What Livdelzi Looks Like (and How to Identify It Safely)

You’re right to care about “pictures” and identification. Medication errors happen, and “it looked kind of blue-ish” is not a safe identification method.

Capsule description (typical U.S. product labeling)

• Strength: 10 mg capsule
• Appearance: opaque hard capsule with a dark blue cap and light gray body
• Imprint: “CBAY” on the cap and “10” on the body

Safety tips for “pill picture” searches

• Use the imprint + shape + color combination, not color alone.
• Match the imprint exactly (letters/numbers/spacing).
• If anything seems off (wrong imprint, unusual packaging, crumbling capsule), don’t take itcall your pharmacist.

Monitoring: What Your Clinician May Track

PBC treatment is a long game. Livdelzi isn’t a “take it and forget it” medmonitoring helps confirm benefit and catch problems early.
Depending on your situation, your care team may monitor:

• Liver tests: ALP, bilirubin, AST, ALT (baseline and periodically)
• Symptoms: itching severity, fatigue, abdominal symptoms, signs of decompensation if cirrhosis is present
• Bone health: fracture risk assessment, and sometimes bone density evaluation
• Kidney-related labs: especially if you have other risk factors or your labs change

If you like having a practical plan, ask your clinician: “Which labs are we using to define success for me, and when will we re-check them?”
That one question can turn anxiety into a calendar reminder.

FAQ (Because Your Brain Will Ask These at 2:00 a.m.)

Does Livdelzi cure PBC?

No. It treats PBC by improving cholestasis-related markers and, for some people, symptoms like itching.
It’s aimed at disease control, not a cure.

How fast can it work?

In clinical studies, improvements in ALP were seen as early as about one month, with effects maintained through longer follow-up in trials.
Real-world response varies, especially depending on baseline labs and whether you’re also on UDCA.

Can I take it with food?

Yes. It’s generally taken once daily with or without food.

What if I have advanced liver disease?

Livdelzi is generally not recommended in people who have or develop decompensated cirrhosis.
If you have cirrhosis, your specialist will weigh risks carefully and monitor for signs of decompensation.

Can Livdelzi be used with itch medications?

Sometimes, yesbut timing matters. Bile acid sequestrants need spacing (4 hours apart), and rifampin can affect drug exposure.
This is exactly the kind of “small detail, big consequences” area where your pharmacist shines.

Experiences: What Living With Livdelzi Can Feel Like (About )

Let’s talk about “experiences” the responsible way: what follows are composite, realistic scenarios based on patterns commonly discussed
in clinical care and clinical trial reportingnot promises, not guarantees, and not a substitute for your own medical advice.
PBC is personal; treatment is personal; your liver didn’t read the same pamphlet as anyone else’s.

The “Lab-Scoreboard” Phase

Many people start Livdelzi with a weird mix of hope and skepticism. Hope because they’ve been staring at ALP results that just won’t behave.
Skepticism because they’ve already tried “the obvious first-line med” (UDCA) and got a “meh” response.
A common early experience is that the first few weeks feel… normal. No fireworks. Then a follow-up lab panel shows ALP trending down.
That moment is oddly emotional: it’s not a symptom you can feel, but it’s a sign the internal traffic jam may be clearing.
Clinicians often frame this as “biochemical response,” and patients often translate it as “finally, my numbers aren’t trying to pick a fight.”

The “Itch Diary” and the Great Calendar Juggle

If itching is part of your PBC story, you might find yourself tracking it like a weather app: “today’s itch index is… rude.”
Some patients in clinical studies with significant baseline pruritus showed bigger itch improvement on Livdelzi than placebo by around 6 months.
In real life, people who notice improvement often describe it as less “I need sandpaper” and more “I can wear a sweater without regretting everything.”
But there’s a practical challenge: if you also take a bile acid sequestrant (like cholestyramine), the timing matters.
A lot of folks become accidental scheduling expertsLivdelzi at breakfast, resin mid-day, and a phone alarm that basically runs their life.
It’s not glamorous, but it’s doable, and many find that once the routine settles, it’s just another habitlike flossing, but with more liver enzymes involved.

The “Side-Effect Detective” Weeks

The most common side effects reported include headache, nausea, dizziness, and abdominal discomfort or bloating.
When these happen, they’re often mild-to-moderate, and many people manage them by adjusting meal timing, hydration, and checking for other culprits
(hello, coffee on an empty stomach). The smart move is to keep notes: what time you took the capsule, what you ate, what symptoms showed up, and how long they lasted.
Not because you need to become your own clinical trial, but because patterns help your clinician fine-tune the plan.

The “Bone Health Grown-Up Conversation”

The fracture warning surprises some peopleuntil they remember that chronic liver disease and cholestasis can already raise bone health concerns.
A common experience is a proactive pivot: a clinician asks about past fractures, calcium/vitamin D intake, weight-bearing exercise,
and whether bone density testing is appropriate. Patients sometimes joke that they came in for liver meds and left with a lecture about squats.
But honestly? It’s a good trade. A stronger skeleton is an underrated life upgrade.

The thread through most experiences is this: Livdelzi tends to become part of a bigger PBC strategymeds, monitoring, symptom management,
and regular check-insrather than a magic wand. The goal is steadier labs, better quality of life, and fewer surprises.

Conclusion

Livdelzi (seladelpar) is a once-daily oral capsule for adults with primary biliary cholangitis, used with UDCA when UDCA isn’t enough or alone when UDCA isn’t tolerated.
It’s approved based on improvements in key lab markers like ALP, with additional evidence suggesting benefit for itching in people who start out with significant pruritus.
Like any serious medication, it comes with real cautionsespecially fracture risk, liver test monitoring, and important interactions (hello, bile acid sequestrants).
If you’re considering Livdelzi or already taking it, the best next step is a practical one: review your medication list with your clinician/pharmacist and agree on a lab-monitoring plan you understand.